Roche’s TIGIT drug misses overall survival endpoint in Phase 3 lung cancer trial

Roche’s TIGIT drug has failed to clear the final hurdle in a late-stage cancer trial in what’s proving to be a mostly disappointing year for a drug class that was once seen as the next ...